Associating a negatively charged GdDOTA-derivative to the Pittsburgh compound B for targeting Aβ amyloid aggregates

Oliveira, Alexandre C.; Laurents, Douglas V.; Tóth, Éva; Geraldes, Carlos F. G. C.

doi:10.1007/s00775-015-1316-9

Cited by 20 publications

(23 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 Gd(III)-DOTA and its analogs are commonly known to be efficient contrast agents in clinical MRI and find use in many theranostic applications. [24][25][26][27][28][29][30] The described biotin-labelled Gd(III)-DOTA conjugate successfully delivered a highly potent cytostatic, camptothecin, into cancer cells and allowed for real-time imaging of its distribution and cellular uptake in vivo. Administration of the pure anti-tumour drug resulted in severe side effects due to the induced apoptosis of healthy cells.…”

Section: Lanthanide Conjugates In Diagnostics and Therapymentioning

confidence: 99%

Lanthanide conjugates as versatile instruments for therapy and diagnostics

Herlan

Bräse

2020

Dalton Trans.

View full text Add to dashboard Cite

show abstract

Section: Lanthanide Conjugates In Diagnostics and Therapymentioning

confidence: 99%

Lanthanide conjugates as versatile instruments for therapy and diagnostics

Herlan

Bräse

2020

Dalton Trans.

View full text Add to dashboard Cite

show abstract

“…We have recently developed a series of contrast agents based on conjugation of PiB derivatives, through different linkers, to DO3A‐monoamide or DOTA (Figure ) . The chelating units ensure stable Gd 3+ complexes for MRI, but the coordination of other trivalent metal ions is also possible to create probes for single‐photon emission computed tomography (SPECT) with 111 In 3+ or PET with 68 Ga 3+ .…”

Section: Targeted Probesmentioning

confidence: 99%

“…[44] We have recentlyd evelopedas eries of contrast agents based on conjugation of PiB derivatives, through different linkers, to DO3A-monoamide or DOTA( Figure 6). [45][46][47][48] The chelat- Figure 5. Lanthanide complexesmodeling the enzymatic probe before (L 5 )a nd after( L 6 )enzymaticcleavage.…”

Section: Targeting Amyloidpeptidesmentioning

confidence: 99%

Lanthanide Complexes in Molecular Magnetic Resonance Imaging and Theranostics

Lacerda

Tóth

2017

ChemMedChem

Self Cite

View full text Add to dashboard Cite

Lanthanide complexes have attracted much attention in the biomedical field, and today various imaging applications make use of their versatile magnetic and luminescence properties. In this minireview, we give insight into the mechanistic aspects that allow modulation of the relaxation or chemical exchange saturation transfer (CEST) features, and thus the magnetic resonance imaging (MRI) efficiency of paramagnetic lanthanide chelates in order to create agents that are capable of providing an MRI response as a function of a specific biomarker. We focus on the detection of neurotransmitters, enzymatic activities, and amyloid peptides. We also describe two selected theranostic strategies: 1) a novel approach directed at monitoring drug release from liponanoparticles and 2) molecular or nanoparticle probes for the MRI visualization of photosensitizer delivery in photodynamic therapy.

show abstract

“…Macrocyclic polyamine compounds have a strong affinity for metals ions [21] and have found applications in diagnostic imaging, as therapeutic agents [22][23][24] and in targeting Aβ amyloid aggregation [25]. These compounds have important physical properties such as low molecular weights, neutral charge, amphiphilic solubility and low toxicities [22].…”

Section: Introductionmentioning

confidence: 99%

Cyclen-based chelators for the inhibition of Aβ aggregation: Synthesis, anti-oxidant and aggregation evaluation

Safadi

Bhadbhade

Shimmon

et al. 2017

Inorganica Chimica Acta

View full text Add to dashboard Cite

The aggregation of the protein amyloid-β in the brain has been associated with neurodegenerative diseases such as Alzheimer's disease. Such aggregation of amyloid-β can be induced by misregulated metal ions such as Cu 2+ and Zn 2+. Here we present a series of four metal chelating compounds based on the cyclen macrocycle that bears pendant arms to provide additional anti-oxidant activity. The corresponding Cu 2+ , Zn 2+ and Ni 2+ complexes have been synthesized and characterized to examine the ability of the chelators to bind to the metal centres. Aβ40 de-aggregation by the cyclen compounds was assessed using turbidometry and the re-solubilization of the Aβ40 was also examined. Our results show that the cyclen compounds have the ability to effectively chelate Cu 2+ and Zn 2+ metal ions and thus de-aggregate Aβ40 that has been aggregated due to the presence of these ions. The antioxidant properties of the cyclen compounds was tested by using the DPPH scavenging assay and the results show that some of the compounds can decrease oxidative stress.

show abstract

Associating a negatively charged GdDOTA-derivative to the Pittsburgh compound B for targeting Aβ amyloid aggregates

Cited by 20 publications

References 101 publications

Lanthanide conjugates as versatile instruments for therapy and diagnostics

Lanthanide conjugates as versatile instruments for therapy and diagnostics

Lanthanide Complexes in Molecular Magnetic Resonance Imaging and Theranostics

Cyclen-based chelators for the inhibition of Aβ aggregation: Synthesis, anti-oxidant and aggregation evaluation

Contact Info

Product

Resources

About